Looks interesting. Just started trading on Nasdaq in the last few weeks.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 21 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and at least two additional programs expected to enter Phase 1 and Phase 2 clinical trials in the next 12 months. For further information, please visit www.gwpharm.com

Thanks to you all for provoiding this information to us!

The below statement is what I am most interested in. Does Al Mann really feel that they will have 450,000 users by the end of next year? Or that they can reach sales of full capacity once built out by the end of 2015? I mean is this even possible?

"Product sales will grow as fast as MNKD can expand and make the product.Current treatment capacity at Danbury facility is 450,000 patients/year but 2 million patients per year could easily be attained with additional equipment".

Thats $320 a month nada and all of us have been talking $220 a month for Afrezza?

Never seen that before brentie! Thanks for the good laugh!

Dreggy,

The extra year might be the true leverage needed to really see how Afrezza sales are doing. So on the downside yes both will be toast but on the upside the warrants got an extra year to see what will become of Mannkind.

Random upside potential like the TechnoVax partnership is worth less leverage and the extra 13 months IMO! Cancer drugs, technosphere, TechnoVax, Tolero, Afrezza, fast track potential, 2 billion worth of write offs, 40 million shorts, wineblast, numerous patents, so much long term potential for that random news some day.